The NFL trade market was nearly upended this week by a deal that never happened. According to league insiders, the Los Angeles Rams were lining up a transformative multi-team swap to acquire Philadelphia Eagles wide receiver AJ Brown, a move so massive it required the simultaneous exploration of trading away veteran Davante Adams to balance the financial scales.
However, the high-stakes negotiations came to an abrupt halt when the Rams‘ front office received the results of preliminary medical research.
The findings, which highlighted significant “wear and tear” on the 28-year-old’s lower body, reportedly scared off Los Angeles officials, who ultimately deemed the required draft capital too steep an investment for a player with a mounting injury file.
The medical concerns surrounding Brown are not merely speculative; they are rooted in a grueling 2024 season that saw the receiver push his physical limits to help Philadelphia secure a Super Bowl LIX victory.
During a revelatory appearance on the Pardon My Take podcast in August 2025, Brown admitted that his postseason heroics required extreme medical intervention.
He revealed that he had his knee drained twice a week throughout the Eagles‘ championship run, including a final procedure performed just hours before the Super Bowl itself.
While Brown emphasized his “grit” during the interview, the admission provided rival scouts and medical staffs with a roadmap of potential degenerative issues that have seemingly impacted his trade value in the 2026 offseason.
Hurdles for potential suitors
The Rams‘ hesitation reflects a growing league-wide caution regarding Brown’s long-term durability. Philadelphia Inquirer reporter Jeff McLane recently noted that a series of hamstring “flare-ups” in late 2025 were attributed to “scar tissue” from previous injuries.
This diagnosis points to a chronic condition rather than an isolated incident, fueling fears that the explosive, physical style that made Brown a three-time Pro Bowler is beginning to take a permanent toll on his frame.
The financial and competitive implications of these medical reports are substantial for Philadelphia General Manager Howie Roseman. The Eagles have reportedly set a steep asking price for their star wideout: a 2026 first-round pick, a second-round pick, and a roster player.
Alternatively, insider Josina Anderson reported that Philly would consider a 2027 first-rounder paired with a 2026 second-rounder. However, as NBC’s Mike Florio noted, the Rams decided the “general wear and tear” made that price point untenable.
“They decided too much of an investment for a player at this age… ‘we’re not going to do it,'” Florio stated.
Read the full article here
